Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2022 | Amyloidosis Sessions: Highlights from ISA 2022

Morie Gertz and Vaishali Sanchorawala • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab

Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session a discussion from the 18th Meeting of the International Society of Amyloidosis (ISA) with leading experts Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, and Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, who share their highlights in amyloidosis from the meeting.

More from Morie Gertz

Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis 1:36
Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz • 21 Nov 2022
The role of allogeneic transplantation in patients with multiple myeloma 1:33
The role of allogeneic transplantation in patients with multiple myeloma
Morie Gertz • 21 Nov 2022
The importance of identifying AH amyloidosis in patients with normal free light chain levels 1:34
The importance of identifying AH amyloidosis in patients with normal free light chain levels
Morie Gertz • 21 Nov 2022
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma 1:37
MRD as a prognostic tool but not for clinical decision-making in multiple myeloma
Morie Gertz • 21 Nov 2022

More from Vaishali Sanchorawala

Amyloidosis Sessions: Highlights from ASH 2024
Ashutosh Wechalekar et al. • 8 Dec 2024
Clinical outcomes of patients with AL amyloidosis with acquired factor X deficiency 1:34
Clinical outcomes of patients with AL amyloidosis with acquired factor X deficiency
Vaishali Sanchorawala • 8 Dec 2024
Updated results of the ANDROMEDA trial: daratumumab + CyBorD versus CyBorD alone in AL amyloidosis 2:21
Updated results of the ANDROMEDA trial: daratumumab + CyBorD versus CyBorD alone in AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2024
A retrospective study assessing the value of MRD assessment in AL amyloidosis 1:24
A retrospective study assessing the value of MRD assessment in AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2024

Related Videos

Refining the diagnosis and classification of CMML 6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
Improving the diagnosis of amyloidosis: advice that can be applied in practice 2:48
Improving the diagnosis of amyloidosis: advice that can be applied in practice
Gareth Morgan • 18 Sep 2025
Ongoing research in gray zone lymphoma 1:07
Ongoing research in gray zone lymphoma
Kieron Dunleavy • 4 Sep 2025
Insights into gray zone lymphoma: a rare subtype of NHL 1:14
Insights into gray zone lymphoma: a rare subtype of NHL
Kieron Dunleavy • 4 Sep 2025
The content of VJHemOnc is intended for healthcare professionals